Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL).

Abstract:

:The t(1;19)(q23;p13), a non-random chromosome rearrangement associated with childhood pre-B acute lymphoblastic leukemia (ALL), results at molecular level in the hybrid E2A-PBX1 gene. This gene is expressed in a typical set of fusion transcripts and oncogenic chimeric proteins. However, the occurrence of t(1;19) molecular variants has been recently suggested. In an attempt to identify these variants, we analyzed 25 pediatric cases of pre-B cIg+ cell ALL. We used Southern blot analysis to detect E2A gene rearrangements and RT-PCR to detect chimeric E2A-pbx1 transcripts. In addition to seven cases with the molecular pattern usually associated with the t(1;19), we identified three molecular variants. In one case, a variant E2A-pbx1 transcript showed 27 additional base pairs inserted in frame at the junction site. In two cases, Southern blot evidenced the expected E2A gene rearrangements. However, extensive RT-PCR analysis failed to detect any E2A-pbx1 transcript. These findings led us to hypothesize that a gene other than PBX1 might be involved in these 1;19 variant translocations.

journal_name

Leukemia

journal_title

Leukemia

authors

Privitera E,Luciano A,Ronchetti D,Aricò M,Santostasi T,Basso G,Biondi A

subject

Has Abstract

pub_date

1994-04-01 00:00:00

pages

554-9

issue

4

eissn

0887-6924

issn

1476-5551

journal_volume

8

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00

  • RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

    abstract::Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. A...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0403-2

    authors: Zhou N,Gutierrez-Uzquiza A,Zheng XY,Chang R,Vogl DT,Garfall AL,Bernabei L,Saraf A,Florens L,Washburn MP,Illendula A,Bushweller JH,Busino L

    更新日期:2019-08-01 00:00:00

  • Role of cytokines in the treatment of acute leukemias: a review.

    abstract::Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia an...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404152

    authors: Ravandi F

    更新日期:2006-04-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract::Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401783

    authors: Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期:2000-06-01 00:00:00

  • Variant translocation t(3;15)(q21;q22) in a patient with acute promyelocytic leukemia.

    abstract::Bone marrow cells from most patients with acute promyelocytic leukemia contain a highly specific cytogenetic rearrangement, a reciprocal translocation between the long arms of chromosomes 15 and 17. Several cases of variant translocations involving 17q but not 15q have been reported, leading to the suggestion that the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Heim S,Kristoffersson U,Mandahl N,Malm C,Mitelman F

    更新日期:1988-01-01 00:00:00

  • Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia.

    abstract::The clinical and laboratory features of 23 patients with a characteristic form of splenic lymphoma with circulating "villous" lymphocytes (SLVL) are described and compared with those of other B cell disorders with preferential splenic involvement. SLVL affects predominantly men in their early 70's and is characterized...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Melo JV,Robinson DS,Gregory C,Catovsky D

    更新日期:1987-04-01 00:00:00

  • International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

    abstract::In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous ...

    journal_title:Leukemia

    pub_type: 杂志文章,实务指引,评审

    doi:10.1038/leu.2009.122

    authors: Palumbo A,Sezer O,Kyle R,Miguel JS,Orlowski RZ,Moreau P,Niesvizky R,Morgan G,Comenzo R,Sonneveld P,Kumar S,Hajek R,Giralt S,Bringhen S,Anderson KC,Richardson PG,Cavo M,Davies F,Bladé J,Einsele H,Dimopoulos MA,Sp

    更新日期:2009-10-01 00:00:00

  • The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome).

    abstract::We previously demonstrated that the EVI-1 gene was transcriptionally activated in the 3q21q26 syndrome and chromosomal breakpoints at 3q26 were clustered within 400 Kb of the EVI-1 gene. Since thrombocytosis is often observed in the 3q21q26 syndrome, we first mapped the thrombopoietin (TPO) gene and then we examined f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Suzukawa K,Satoh H,Taniwaki M,Yokota J,Morishita K

    更新日期:1995-08-01 00:00:00

  • Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.

    abstract::The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in long-term complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or rel...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401128

    authors: Marcucci G,Livak KJ,Bi W,Strout MP,Bloomfield CD,Caligiuri MA

    更新日期:1998-09-01 00:00:00

  • Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

    abstract::The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404638

    authors: Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

    更新日期:2007-06-01 00:00:00

  • Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.

    abstract::Myelodysplastic syndrome (MDS) in children is often considered as a variant of acute myeloid leukemia (AML) and frequently treated as such. However, there are very few reported data on the outcome following AML treatment. We analyzed 20 consecutive cases of de novo MDS treated in Denmark according to the NOPHO AML pro...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hasle H,Kerndrup G,Yssing M,Clausen N,Ostergaard E,Jacobsen N,Jacobsen BB

    更新日期:1996-08-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract::Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.147

    authors: Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期:2016-11-01 00:00:00

  • Somatic hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular lymphoma and multiple myeloma.

    abstract::In this study, we analyzed the targeting of the somatic hypermutation (SHM) mechanism at specific hotspot sequence motifs in the V(H) and Vkappa genes of 10 follicular lymphoma (FL) cases and the Vkappa and Vlambda genes of 11 kappa- and six lamda-light chain expressing multiple myeloma (MM) cases. These sequences wer...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402258

    authors: Belessi C,Stamatopoulos K,Stavroyianni N,Zoi K,Papadaki T,Kosmas C

    更新日期:2001-11-01 00:00:00

  • The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

    abstract::Improved survival of patients with acute lymphoblastic leukemia (ALL) has emerged from identifying new prognostic markers; however, 20% of children still suffer recurrence. Previously, the altered expression of Fat1 cadherin has been implicated in a number of solid tumors. In this report, in vitro analysis shows that ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.319

    authors: de Bock CE,Ardjmand A,Molloy TJ,Bone SM,Johnstone D,Campbell DM,Shipman KL,Yeadon TM,Holst J,Spanevello MD,Nelmes G,Catchpoole DR,Lincz LF,Boyd AW,Burns GF,Thorne RF

    更新日期:2012-05-01 00:00:00

  • General Report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997.

    abstract::Seventeen cytogenetic laboratories in eight European countries contributed karyotypic, hematological, clinical and follow-up data from 550 patients with an acquired abnormality of 11q23. The patients had acute lymphoblastic leukemia (254), acute myeloid leukemia (250), unspecified, undifferentiated, biphenotypic acute...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401011

    authors: Secker-Walker LM

    更新日期:1998-05-01 00:00:00

  • A new t(2;5) translocation in a null cell type CD30 positive anaplastic large cell lymphoma case.

    abstract::Anaplastic large cell lymphoma (ALCL) expressing the CD30 antigen is an uncommon subtype of non-Hodgkin's lymphoma characterized by distinct morphological and clinical features. The recurrent chromosomal abnormality found in these tumours is a t(2;5)(p23;q35) which has been detected in a minority of these cases, predo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wlodarska I,De Wolf-Peeters C,Michaux L,Mecucci C,Verhoef G,Cassiman JJ,Van den Berghe H

    更新日期:1995-10-01 00:00:00

  • Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

    abstract::Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.24

    authors: Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

    更新日期:2012-07-01 00:00:00

  • Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.

    abstract::In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403126

    authors: Collisson EA,Lashkari A,Malone R,Paquette R,Emmanouilides C,Territo MC,Schiller GJ

    更新日期:2003-11-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • A paradigm shift in myelodysplastic syndromes.

    abstract::A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

    更新日期:1996-10-01 00:00:00

  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract::Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0856-3

    authors: Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期:2020-05-12 00:00:00

  • Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia.

    abstract::The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential out...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Duval M,Yotnda P,Bensussan A,Oudhiri N,Guidal C,Rohrlich P,Boumsell L,Grandchamp B,Vilmer E

    更新日期:1995-05-01 00:00:00

  • New chemotherapeutic agents in acute myeloid leukemia.

    abstract::Only two classes of chemotherapeutic agents have shown activity in acute myeloid leukemia (AML): ara-C and topoisomerase II reactive agents. Frontline combinations of these agents produce complete response (CR) rates of 70% and long-term event free survival rates of 25%. New agents with different mechanisms of action ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Kantarjian HM,Estey EH,Keating MA

    更新日期:1996-04-01 00:00:00

  • Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

    abstract::JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0638-y

    authors: Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

    更新日期:2020-04-01 00:00:00

  • Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

    abstract::Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404681

    authors: Jiménez M,Ercilla G,Martínez C

    更新日期:2007-08-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract::Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405087

    authors: San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期:2008-04-01 00:00:00

  • Chromosomal rearrangement on chromosome 11q14-q21 in T cell acute lymphoblastic leukemia.

    abstract::Deletion and translocation involving the bands 11q14 and 11q21 have been detected in five patients with T cell acute lymphoblastic leukemia (ALL). The breakpoint on chromosome 11 was on the same band as that previously described in some acute nonlymphocytic leukemias: monocytic or myelomocytic. The existence of a new ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Berger R,Le Coniat M,Derré J,Vecchione D,Chen SJ

    更新日期:1989-08-01 00:00:00

  • Allelotype analysis of the myelodysplastic syndrome.

    abstract::Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders found predominantly in the elderly. The molecular mechanisms underlying the development of MDS remain obscure. In order to begin to identify tumor suppressor genes involved in these disorders, we performed a detailed microsatellite allelotype ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401717

    authors: Xie D,Hofmann WK,Mori N,Miller CW,Hoelzer D,Koeffler HP

    更新日期:2000-05-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract::In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2014.60

    authors: Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期:2014-08-01 00:00:00

  • Leptin receptor, a surface marker for a subset of highly engrafting long-term functional hematopoietic stem cells.

    abstract::The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01079-z

    authors: Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

    更新日期:2020-11-07 00:00:00